에 대한 최신 뉴스 Schrodinger (NASDAQ:SDGR) 주식

Schrodinger

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Inc

Schrödinger misses top-line and bottom-line estimates; updates FY24 outlook

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Schrödinger gains on Novartis deal despite Q3 miss

Analyst Brendan Smith from TD Cowen maintained a Buy rating on Schrodinger (SDGR – Research Report) and keeping the price target at $33.00. Brendan...

Positive Outlook for Schrödinger: Buy Rating Based on Strategic Partnerships and Growth Potential

In a report released today, Scott Schoenhaus from KeyBanc maintained a Buy rating on Schrodinger (SDGR – Research Report), with a price target of $...

KeyBanc Keeps Their Buy Rating on Schrodinger (SDGR)

BMO Capital raised the firm's price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The company reported...

Schrodinger price target raised to $28 from $25 at BMO Capital

Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 resul...

Schrodinger price target raised to $28 from $27 at Goldman Sachs

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on SDGR stock, giving a Buy rating yesterday. Mani Foroohar has given hi...

Schrodinger's Strategic Collaborations and Financial Position Bolster Buy Rating Amid Market Confidence and Future Growth Potential

Schrodinger (SDGR) announced that it is broadening and accelerating its initiative to expand the company's computational platform to predict toxico...

Schrodinger gets additional funding to expand toxicology risk initiative

Schrödinger: Positive Signs Despite The Share Price Decline

NVSEF

SDGR

Press Releases

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Schrödinger Reports Third Quarter 2024 Financial Results

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

BMO Capital

Morgan Stanley

Keybanc

Leerink Partners

Citigroup

Comments

Schrodinger

뉴스

에 대한 최신 뉴스 Schrodinger (NASDAQ:SDGR) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌